ArticleJournal of applied biomedicine2019
Versatile biomedical potential of biosynthesized silver nanoparticles from Acacia nilotica bark.
Article in Journal of applied biomedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Forest Tree and Woody Plant-Based Biosynthesis of Nanoparticles and Their Applications.Nanomaterials (Basel, Switzerland) · 2025Review
- Unleashing the promise of emerging nanomaterials as a sustainable platform to mitigate antimicrobial resistance.RSC advances · 2024Review
- Recent Advances in Green Synthesis of Ag NPs for Extenuating Antimicrobial Resistance.Nanomaterials (Basel, Switzerland) · 2022Review
- The use of nanoparticles as alternative therapeutic agents against Candida infections: an up-to-date overview and future perspectives.World journal of microbiology & biotechnology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The present study reports the development of potent silver nanoparticles (AgNPs) using bark extract of Acacia nilotica and evaluation of its wound healing, anti-biofilm, anti-cancer and anti-microbial activity. Stable, small sized nanoparticles with spherical morphology were obtained after significant optimization studies that was evaluated through UV-visible spectroscopy. Thereafter, physicochemical characterization of biosynthesized AgNPs was carried out through DLS and FESEM for evaluation of size. EDAX and FTIR were carried out for the evaluation of composition and possible functional groups involved in the reduction and capping of AgNPs. The antibacterial potential was investigated through disc diffusion assay against Escherichia coli (E. coli) and Pseudomonas aeruginosa (P. aeruginosa). Further, the Congo Red Assay (CRA) successfully revealed the anti-biofilm activity against Bacillus subtilis (B. subtilis), Staphylococcus aureus (S. aureus), Proteus vulgaris (P. vulgaris), Pseudomonas aeruginosa (P. aeruginosa). Alamar blue assay was conducted in A549 cells to reveal the remarkable anticancer activity of biosynthesized AgNPs that resulted in a very appreciable manner. Further, the wound healing activity of AgNPs can heal the excised wound of mice up-to 100% within 15 days. All these studies suggested that our biosynthesized AgNPs possess versatile biomedical application.
Indexed as
Identifiers
34907733What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.